Managing aromatase inhibitor-associated bone loss in breast cancer

Author： Lipton Allan   Gnant Michael   Aapro Matti  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.3, Iss.4, 2007-07, pp. : 441-448

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pilot study of Iyengar yoga for management of aromatase inhibitor‐associated arthralgia in women with breast cancer

By  

PSYCHO-ONCOLOGY (ELECTRONIC), Vol. 24, Iss. 11, 2015-11 ,pp. : 1578-1580

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rivizor – A New Third-Generation Aromatase Inhibitor for the Treatment of Advanced Breast Cancer after Tamoxifen Failure

By  

Oncology, Vol. 56, Iss. 2, 1999-02 ,pp. : 114-121

Karger

Access to resources Recommend Favorite

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 10, 2015-11 ,pp. : 2513-2519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor‐related arthralgia: A randomized trial

By  

CANCER, Vol. 120, Iss. 23, 2014-12 ,pp. : 3744-3751

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women

By Mouridsen Henning T.  

Current Medical Research and Opinion, Vol. 22, Iss. 8, 2006-08 ,pp. : 1609-1621

Informa Healthcare

Access to resources Recommend Favorite